What is Morphocell Technologies?
Morphocell Technologies, established in 2018 and based in Montreal, is a pioneering regenerative medicine firm dedicated to creating stem cell-derived tissue and organ replacement therapies. Leveraging a proprietary induced pluripotent stem cell (iPSC) platform, the company is building a comprehensive pipeline of tissue-engineered treatments aimed at severe organ dysfunctions, with an initial focus on liver disease. Morphocell integrates scientific rigor, clinical acumen, and advanced manufacturing capabilities to advance next-generation regenerative therapies for patients globally.
How much funding has Morphocell Technologies raised?
Morphocell Technologies has raised a total of $50M across 1 funding round:
Series A
$50M
Series A (2025): $50M with participation from Investissement Quebec and CDP Venture Capital SGR
Key Investors in Morphocell Technologies
Investissement Quebec
Investissement Quebec is a provincial entity focused on fostering economic development and job creation in Quebec through various financial solutions, including equity investments.
CDP Venture Capital SGR
CDP Venture Capital SGR is a prominent Italian venture capital fund manager that invests in sectors critical to Italy's growth, with a strategic focus on innovation and sustainability.
What's next for Morphocell Technologies?
The substantial enterprise-level funding and strategic investment signal a pivotal moment for Morphocell Technologies, likely enabling the company to accelerate its clinical development pipeline, scale manufacturing operations, and potentially pursue regulatory approvals for its innovative organ replacement therapies. This capital infusion is expected to propel Morphocell towards its goal of bringing life-changing regenerative treatments to market, particularly for patients suffering from debilitating liver conditions.
See full Morphocell Technologies company page
